RCM
IOVA icon

Requisite Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Requisite Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-145,000
Closed -$1.38M – 152
2019
Q1 		$1.38M Sell
145,000
-5,000
-3% -$48.6K 0.53% 25
2018
Q4 		$1.33M Buy
+150,000
New +$1.45M 0.52% 22

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Requisite Capital Management's IOVA Position: Q2 2019 in Review

Requisite Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2019, closing a stake of 145,000 shares — an estimated $1.38M sold.

Requisite Capital Management first reported a position in IOVA in Q4 2018 and held it in 2 quarters. The position peaked at $1.38M in Q1 2019. 167 funds tracked by Wall St. Rank hold IOVA as of Q2 2019.

  • Requisite Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Requisite Capital Management sold 145,000 Iovance Biotherapeutics shares in Q2 2019, an estimated $1.38M.
  • Requisite Capital Management first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 2 quarters.
  • Requisite Capital Management's Iovance Biotherapeutics position peaked at $1.38M in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2019.

Based on Requisite Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.